Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corautus submits response to FDA

This article was originally published in Clinica

Executive Summary

Corautus Genetics has filed a response to the US FDA regarding the agency's clinical hold on a trial of its investigational VEGF-2 gene therapy product for angina. The hold had been imposed due to potential safety concerns with the delivery of the product, and in April 2006, Corautus decided to terminate the enrolment in the trial - called GENASIS - after 295 patients had already been treated. "We did not, and still do not, believe the events were related to the therapeutic," said Richard Otto, the Atlanta, Georgia firm's president and CEO. The company's response to the FDA was developed after evaluating the safety concerns with its partner Boston Scientific, maker of the Stiletto catheter system used to deliver the VEGF product percutaneously. The company is still hopeful that it will be able to start a phase III clinical trial of the product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel